25 stem cell & regenerative medicine predictions for 2025

regenerative medicine, stem cell predictions

Toward the end of each year I make predictions for the stem cell and regenerative medicine field for the coming year. I’ve been doing this for more than a dozen years in various forms. In this post I’m looking at the (gene-edited, stemness enriched) tea leaves for 2025 for the regenerative arena. These predictions include […]

25 stem cell & regenerative medicine predictions for 2025 Read More »

Weekly stem cell reads: HSCT, old embryo models, aging stem cells

stem cell

What is a stem cell therapy? Does it have to include stem cells put into the body? Would you include a therapy that uses differentiated cells made from stem cells? I generally do use the term in that broader way. A similar question comes to mind: what is regenerative medicine? Should it include both cell

Weekly stem cell reads: HSCT, old embryo models, aging stem cells Read More »

QC Kinetix review: concerns on huge regenerative clinic chain

Tyler Vail, QC Kinetix

QC Kinetix is a relatively new regenerative clinic brand in the U.S. selling unproven cell therapies. I see several specific red flags including a class action lawsuit. They report having 150+ locations, making it potentially the largest chain of unproven clinics in the U.S. Collectively, these clinics could be seeing tens of thousands of customers.

QC Kinetix review: concerns on huge regenerative clinic chain Read More »

Refreshing WSJ piece on longevity ‘guru’ David Sinclair

David sinclair, anti-aging

I’ve written before about concerns related to longevity research hype from Harvard professor David Sinclair. The media often eats up statements about longevity from Sinclair and a few other scientists in that space. There is also endless coverage of the latest exploits of wealthy health influencer Bryan Johnson. For that reason it was refreshing to

Refreshing WSJ piece on longevity ‘guru’ David Sinclair Read More »

Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells

cellular aging

Do our aging cells necessitate that we age overall as people? Flipping it around, if we can stop or reverse enough cellular aging, will our overall aging be positively affected? It’s clear that people age very differently from each other and so do our cells and organs. Interestingly, intramurally in a sense the cells and

Weekly reads: aging cells, scientists relying on ChatGPT, anemone stem cells Read More »

Positive regenerative medicine story of the year: diabetes & sickle cell were tops

regenerative medicine

What was the biggest upbeat regenerative medicine story of 2024? I have my own favorites but decided to run a poll. Just putting the poll together, it was evident that this year was unusually full of good and encouraging news. Diabetes and sickle cell regenerative medicine therapies In The Niche polling, so far Vertex Type

Positive regenerative medicine story of the year: diabetes & sickle cell were tops Read More »

FDA warns Frontier Biologics as part of its more active trend

Chad W. Justice, Frontier Biologics

The FDA recently warned Frontier Biologics, LLC, a Texas perinatal tissue manufacturer firm. Tallying the many FDA biologics warnings in 2024 It can sometimes feel like there are an uncountable number of unproven stem cell clinics However, the good news is that the FDA has been doing much more on this front in 2024. With

FDA warns Frontier Biologics as part of its more active trend Read More »

Weekly reads: Scott Gottlieb v. RFK Jr., DNA typewriters, Arnold Caplan

Peter-Marks-Scott-Gottlieb-FDA

Remember former Trump’s FDA Commissioner Scott Gottlieb? Gottlieb’s back in the news in an interesting way related to the upcoming second Trump administration. I just wrote about what to expect from new FDA Commissioner nominee Marty Makary. In that piece, I noted that Scott Gottlieb first came to lead the FDA after a record of

Weekly reads: Scott Gottlieb v. RFK Jr., DNA typewriters, Arnold Caplan Read More »

What you need to know about Martin Makary and planning for the Trump 2.0 FDA

Martin Makary, Trump FDA

How might Trump’s nominee to lead the FDA, Martin Makary, change the agency? Should we be worried or hopeful? I’ve been closely following the FDA and its commissioners ever since I started The Niche in 2010. I’ve been particularly interested in how these leaders impacted FDA actions on cell and gene therapies. How might Makaray

What you need to know about Martin Makary and planning for the Trump 2.0 FDA Read More »

Weekly reads: GIOSTAR stem cell clinic IND, cadaver marrow, NIH under Trump 2.0, tweets from a stem cell

Giostar

What happens if unproven stem cell clinic firms like GIOSTAR start getting okays from the FDA to do clinical trials? On the one hand, it could reflect a positive trend of stem cell clinic firms working with the FDA and toward compliance. Having more robust data. However, I worry about some of these types of

Weekly reads: GIOSTAR stem cell clinic IND, cadaver marrow, NIH under Trump 2.0, tweets from a stem cell Read More »

Subscribe to Our Newsletter

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.